Fig. 4: DSF systemically affected B cells and CD138+ plasma cells in vivo at POD9. | Communications Biology

Fig. 4: DSF systemically affected B cells and CD138+ plasma cells in vivo at POD9.

From: Disulfiram treatment suppresses antibody-producing reactions by inhibiting macrophage activation and B cell pyrimidine metabolism

Fig. 4

a Flow cytometry plot of B cells (B220+) and CD138+ plasma cells of draining lymph nodes of the control (left) and DSF group (right). b The number of B220+ cells in draining lymph node (DLN, n = 4 biologically independent mice) and spleen (SPL, n = 4 biologically independent mice) (Syn, syngeneic). c Immunofluorescent staining of B220 + B cells (red) in the spleen of the recipient. d Percentage of CD138+ in B220+ cells in DLN, BM, SPL, and peripheral blood (PB) (n = 3 biologically independent mice). e Percentage of IL-6+ cells in B220+ cells in the spleen (Cont, n = 4; DSF, n = 3 biologically independent mice). A representative gating strategy is displayed in Supplementary Fig. 5c. f Immunofluorescent staining of Ki67 (green) and B220 (red) of the recipient spleen in syngeneic (Syn, upper), Control group (Cont, middle), and DSF group (DSF, down). g Quantification of Ki67 + B220+ cell numbers in the spleen of each recipient (ten fields in three mice). Plasma IL-6 (h) and IFN-gamma (i) level in recipients (syn, n = 4; Cont, n = 8; DSF, n = 7 biologically independent mice). Significance was calculated using a two-tailed, unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data are shown as the mean ± SEM.

Back to article page